Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocodone vs oxycodone sustained‑release tablets for cancer pain (crossover preference study)
ChiCTR2500113704Phase 4Recruiting
- Sponsor
- General Hospital of Eastern Military Command
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hydrocodone and oxycodone in cancer pain (2 arms), sponsored by General Hospital of Eastern Military Command. Primary endpoint: NRS score. Started Dec 2025; status: recruiting.
02
Drugs
hydrocodoneoxycodone
03
Conditions
cancer pain
Beyond the preview
Go deeper on ChiCTR2500113704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113704.